Skip to main content

editorial

. 1978 Dec 9;2(6152):1585–1586. doi: 10.1136/bmj.2.6152.1585

Clofibrate and the primary prevention of ischaemic heart disease.

PMCID: PMC1608867 PMID: 728731

1585

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Carlson L. A., Böttiger L. E. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study. Lancet. 1972 Apr 22;1(7756):865–868. doi: 10.1016/s0140-6736(72)90738-6. [DOI] [PubMed] [Google Scholar]
Dewar H. A., Oliver M. F. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. Br Med J. 1971 Dec 25;4(5790):784–786. doi: 10.1136/bmj.4.5790.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
Mott G. E., McMahan C. A., McGill H. C., Jr Diet and sire effects on serum cholesterol and cholesterol absorption in infant baboons (Papio cynocephalus). Circ Res. 1978 Sep;43(3):364–371. doi: 10.1161/01.res.43.3.364. [DOI] [PubMed] [Google Scholar]
OLIVER M. F. Reduction of serum-lipid and uric-acid levels by an orally active androsterone. Lancet. 1962 Jun 23;1(7243):1321–1323. doi: 10.1016/s0140-6736(62)92422-4. [DOI] [PubMed] [Google Scholar]
THROP J. M. Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate. Lancet. 1962 Jun 23;1(7243):1323–1326. doi: 10.1016/s0140-6736(62)92423-6. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES